HC Wainwright Comments on Gossamer Bio FY2030 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Gossamer Bio in a research report issued on Tuesday, February 10th. HC Wainwright analyst P. Trucchio expects that the company will earn $0.78 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. Barclays initiated coverage on shares of Gossamer Bio in a research note on Tuesday, January 27th. They set an “overweight” rating and a $9.00 target price on the stock. Finally, Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.60.

Gossamer Bio Trading Down 1.3%

GOSS stock opened at $2.29 on Thursday. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87. The firm has a 50-day moving average of $2.86 and a two-hundred day moving average of $2.67. The firm has a market capitalization of $530.04 million, a PE ratio of -3.32 and a beta of 1.93.

Institutional Trading of Gossamer Bio

Several hedge funds and other institutional investors have recently modified their holdings of the company. Walleye Capital LLC boosted its holdings in Gossamer Bio by 97.4% during the fourth quarter. Walleye Capital LLC now owns 1,077,032 shares of the company’s stock valued at $3,339,000 after purchasing an additional 531,353 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in Gossamer Bio in the 4th quarter valued at $44,000. Jacobs Levy Equity Management Inc. boosted its stake in Gossamer Bio by 54.7% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,178,033 shares of the company’s stock valued at $6,752,000 after buying an additional 769,915 shares in the last quarter. Rafferty Asset Management LLC bought a new stake in Gossamer Bio in the fourth quarter valued at $970,000. Finally, State Street Corp raised its stake in Gossamer Bio by 139.7% during the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after acquiring an additional 5,427,302 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.